Enoxaparin in ACS

More documents

Recommendations

Info

Elements of 1ry Endpoint at 1 Year%)Point (%End P12108642All Cause MortalityUFH 10.6%ENOX 10.5%HR0.98(0.90to 1.0707)P=0.776Non-fatal MIUFH6.8%5.7%5 ENOX43 HR0.822(0.73to 0.9292)1P=0.0006000600 50 100 150 200 250 300 350Days00 50 100 150 200 250 300 350DaysSummary-11. The benefits of the ENOX strategytover the UFH strategy in reducingDeath/MI was sustained at 1 yr2. The 1 yr benefit of the ENOXstrategy is driven by the earlyreduction in reMI
Summary-23. Net clinical benefit significantlyfavors the ENOX strategy both at 30days and 1 yr.Clinical Implications for Managementof fSTEMIThe ENOX strategy to support fibrinolysisis preferable to that of UFH:Early superiority in reducing death/MIDurable treatment benefit
Page 1 and 2: Enoxaparin in ACSWhen evidence meet
Page 3 and 4: o DefinitionsAgendao Is UFH w/o dis
Page 5 and 6: Superiority ofEnoxaparin over UFHEv
Page 7 and 8: Coronary patency (TIMI flow 2 or 3)
Page 9 and 10: Enoxaparin versus UFH for STEMIOne
Page 11 and 12: No Increase in ICHents% Ev10UFHENOX
Page 13 and 14: New Data from ExTRACT-TIMI 251YEAR
Page 15: Net Clinical BenefitDeath/MI/Disabl
Page 19 and 20: Enoxaparin and GP IIb/IIIa inhibito
Page 21 and 22: NICE -3Objectiveso To assess the sa
Page 23 and 24: o DefinitionsAgendao Is UFH w/o dis
Page 25 and 26: Clexane in ACS - My ApproachACSCons
Page 27: Egyptian Guidelines for themanageme

Enoxaparin in ACS

Create successful ePaper yourself

Delete template?

Save as template?